FBLG | FibroBiologics, Inc. Common Stock Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.5500 - 1.7600
52 Week Range	1.0780 - 17.75
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	238,558
Average Volume	169,720
Shares Outstanding	34,659,126
Market Cap	57,534,149
Sector	Healthcare
Industry	Biotechnology
IPO Date	2024-02-01

Valuation
Profitability
Growth
Health
P/E Ratio	-3.13
Forward P/E Ratio	N/A
EPS	-0.53
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	10
Country	USA
Website	FBLG

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

*Chart delayed

Analyzing fundamentals for FBLG we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see FBLG Fundamentals page.

Watching at FBLG technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on FBLG Technicals page.